18 F‐fluorodeoxythymidine micro–positron‐emission tomography versus 18 F‐fluorodeoxyglucose micro–positron‐emission tomography for in vivo minimal residual disease imaging
2012; Wiley; Volume: 123; Issue: 1 Linguagem: Inglês
10.1002/lary.23600
ISSN1531-4995
AutoresOleksandr Ekshyyan, Don A. Sibley, Gloria Caldito, John J. Sunderland, Chris Vascoe, Cherie‐Ann O. Nathan,
Tópico(s)Cancer Research and Treatments
ResumoAbstract Objectives/Hypothesis: The early detection of persistent/recurrent disease of head and neck squamous cell carcinoma (HNSCC) after treatment can be challenging. The currently used radioisotope 18 F‐fluorodeoxyglucose (FDG) is a nonspecific tracer for cancer cells as it detects all metabolically active cells including inflammation. 18 F‐fluorodeoxythymidine (FLT) is a radioactive tracer for rapidly proliferating cells, and therefore is more specific for detecting cancer. Our aim was to compare FLT and FDG microPET (positron‐emission tomography) to the gold standard in vivo bioluminescence imaging for serial assessment of neoplastic growth in a minimal residual disease in vivo model. Study Design: Prospective outcomes research. Methods: In order to mimic the postsurgical environment of HNSCC patients FaDu cells transfected with a luciferase‐expressing retrovirus were inoculated into the skin flap of Balb/c nu/nu mice. Three days later before tumors formed, mice were randomized into 18 F‐FLT or 18 F‐FDG groups, and microPET imaging was performed on days 3, 6, 10, 18, and 24 after tumor cell inoculation. Results: 18 F‐FLT detected tumors as early as day 3 even before tumors were palpable, whereas 18 F‐FDG only detected palpable tumors. The average overall normalized radioactivity in the FLT group was significantly higher than the FDG group ( P = .025). Conclusions: 18 F‐FLT identified tumor cells before tumors were palpable and can potentially be used for early detection of persistence/recurrence of HNSCC. In addition, this radioisotope can be used to monitor adjuvant therapy with novel targeted therapeutics in preclinical models of persistent disease. Laryngoscope, 2013
Referência(s)